EQO

About EQO

EQO positions itself as a biotechnology firm focused on the health of aquatic ecosystems. The company applies genomic and transcriptomic analyses to understand and improve the condition of environments like lakes, rivers, and coastal waterways.

The business serves both public and private sector clients who manage or own water assets. This includes entities responsible for lakes, reservoirs, and wetlands that are increasingly stressed by climate change and pollution. EQO's core mission is to utilize environmental genomics to provide clients with high-resolution data on their aquatic environments, enabling proactive measures to protect their health. The company's business model centers on offering advanced diagnostic services and technology platforms to these clients.

EQO has developed proprietary field tools, the Osprey and Calypso platforms, designed to capture environmental RNA (eRNA) and environmental DNA (eDNA) from large water samples. This is a key differentiator, as traditional methods often do not suffice for the high-volume samples required for detailed eRNA and eDNA analysis. The company's services assist clients in three main areas: preventing invasive species infestations, monitoring native and endangered species, and identifying toxic organisms. Beyond sample collection, EQO provides comprehensive lab support, including sample processing, metagenomic analysis, and bioinformatic tools.

The company has participated in multiple funding rounds, including grants and a seed round. Investors include organizations such as the Austin Technology Incubator, America's Seed Fund, and MassChallenge.